Paper40940319
LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer.
Chen S and 5 others. Int J Oral Sci, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. Papers, record 40940319. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940319
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| ErbB Receptors | Major topic |
| Mouth Neoplasms | Major topic |
| RNA, Long Noncoding | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Phosphorylation | |
| Signal Transduction | |
| STAT3 Transcription Factor | |
| Cell Hypoxia | |
| Autophagy | |
| Proto-Oncogene Proteins c-cbl |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82273095, 82203614 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 82203614 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31639425 | EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. | Cancer Lett | 2020 | https://conductscience.org/library/papers/31639425 | PubMed |
| 2 | 21171968 | Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. | J Transl Med | 2010 | https://conductscience.org/library/papers/21171968 | PubMed |
| 3 | 22411794 | Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22411794 | PubMed |
| 4 | 24590058 | STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. | Cancer Res | 2014 | https://conductscience.org/library/papers/24590058 | PubMed |
| 5 | 26282175 | Ligand-Independent EGFR Signaling. | Cancer Res | 2015 | https://conductscience.org/library/papers/26282175 | PubMed |
| 6 | 27163161 | A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. | Autophagy | 2016 | https://conductscience.org/library/papers/27163161 | PubMed |
| 7 | 12829707 | Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12829707 | PubMed |
| 8 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 9 | 17189395 | Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/17189395 | PubMed |
| 10 | 21262846 | Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21262846 | PubMed |
| 11 | 18694561 | Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. | Dev Cell | 2008 | https://conductscience.org/library/papers/18694561 | PubMed |
| 12 | 12717448 | Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. | Nat Cell Biol | 2003 | https://conductscience.org/library/papers/12717448 | PubMed |
| 13 | 16763281 | Epidermal growth factor receptor biology in head and neck cancer. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16763281 | PubMed |
| 14 | 25503978 | Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. | Nat Commun | 2014 | https://conductscience.org/library/papers/25503978 | PubMed |
| 15 | 38499147 | Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. | J Thorac Oncol | 2024 | https://conductscience.org/library/papers/38499147 | PubMed |
| 16 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 17 | 20965422 | Autophagy and the integrated stress response. | Mol Cell | 2010 | https://conductscience.org/library/papers/20965422 | PubMed |
| 18 | 19417138 | The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. | Cancer Res | 2009 | https://conductscience.org/library/papers/19417138 | PubMed |
| 19 | 19229244 | Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. | Cell Death Differ | 2009 | https://conductscience.org/library/papers/19229244 | PubMed |
| 20 | 17218988 | Targeting TACE-dependent EGFR ligand shedding in breast cancer. | J Clin Invest | 2007 | https://conductscience.org/library/papers/17218988 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943257 | Mechanisms and Therapeutic Advances of Natural Products Regulating Non-Coding RNAs in Cancer. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943257 | PubMed |
| 41760308 | Physalin A Suppresses Human Oral Squamous Carcinoma Cell Migration and Invasion Through Inhibiting Grb2/Ras and MMP/uPA Signaling Pathways. | In Vivo | 2026 | https://conductscience.org/library/papers/41760308 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BNIP3 | 664 | PubTator's text mining | https://conductscience.org/library/genes/664 | NCBI Gene |
| CBL | 867 | PubTator's text mining | https://conductscience.org/library/genes/867 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| GRB2 | 2885 | PubTator's text mining | https://conductscience.org/library/genes/2885 | NCBI Gene |
| HIF1A | 3091 | PubTator's text mining | https://conductscience.org/library/genes/3091 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40940319
GET https://conductscience.org/api/papers/v1/40940319/references?page=2